‘Next Cochlear' launches ASX float to sell its ‘medical Lego'
Tetratherix, a medical device company backed by Xero founder Rod Drury, is set to float on the ASX this month, raising $25 million with an ambitious pitch to investors about the potential of its 'medical Lego' product that helps the human body heal faster from injuries and surgery.
The company's product has been in scientific development since 2011, and is built on the work of chief technical officer Ali Fathi, a biomolecular engineer who invented a new material that can be injected into wounds to help tissue and bones heal.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
AU Financial Review
an hour ago
- AU Financial Review
ASIC's IPO tweak helps, but it's not the saviour of public markets
Joe Longo, chairman of the Australian Securities and Investments Commission, has picked the second most obvious piece of low-hanging fruit to show he's doing something to support initial public offerings and Australian-listed equities markets. Tightening IPO timetables is a no-brainer. It takes away some of the market risk for underwriters, who are investors these days, not investment banks, which should encourage investors to buy shares in floats and make it a tad easier for ASX-aspirants to get support for their big listing day.
West Australian
2 hours ago
- West Australian
ASIC shakes up initial public offer rules to solve ‘decade-low' listings dearth
Australia's corporate watchdog will roll out a condensed IPO schedule as part of a two-year trial aimed at solving the stock market's new companies conundrum, in a listings dearth not seen since since the 2010s. The new timetable starts as of Tuesday and will mean, among other changes, that retail investors will get the chance to apply for stock under eligible initial public offers at the same time as wholesale, or sophisticated investors. New companies that expect to land on the ASX with a market capitalisation bigger than $100 million will also be able to submit their 'pathfinder' prospectuses or product disclosures statements confidentially to the Australian Securities and Investments Commission two weeks before the information is released to the public. Announcing the changes, ASIC said being able to 'informally review' offer documents containing the finances, potential risks, history and pricing for a new company earlier — and out of public view — would ultimately reduce admin burden and the risk of spooking investors down the track. 'The changes mean ASIC will engage with an issuer prior to the exposure period, which decreases the need for supplementary and replacement documents and extensions to the exposure period. This also reduces the risk that market volatility and consequential pricing changes may impact investor interest in the IPO.' Despite this seemingly leaving a narrower window for critics to get stuck into a new company's valuations, ASIC assured the changes still allow for concerns to be raised during the public exposure period, and that stock can only be issued once that period has finished. It comes as the corporate regulator sounds out industry and tries to find levers it can pull to make the Australian Securities Exchange a more attractive destination for companies to list. 'Our initial public offerings are the lowest they have been in over a decade, and companies are de-listing,' ASIC chair Joe Longo said. 'Greater deal certainty for companies should help deliver more IPOs, which means more investment opportunities so companies can expand, increase jobs and ultimately economic growth.' Australia's stock market lost 145 companies between December 2022 and December 2024, according to a report commissioned by ASIC, the largest decline over a two-year period since the recession in the early 1990s. The same report said it was too early to tell whether this reflected a cyclical trend or a more structural shift. But ASIC has said it is concerned about the future of the country's public equity markets nonetheless. The rise of Australia's huge superannuation industry and capital flowing to private markets have been attributed as likely drivers of the decline. The same paper suggested a spate of exits from the stock exchange in 2019 and 2020 was due to a clean-up mission instigated by the ASX to automatically delist companies that have been suspended for more than two years. There is conflicting findings on how much regulatory overreach is to blame for the slowdown. 'Australia has not had any substantial changes in the way in which public and private companies are regulated in the last two decades,' ASIC's equity market report released in February read. 'And certainly, no substantial changes coincide with the decline in IPOs and increase in de-listings in 2022-2024.' ASIC's proposed $100 million market capitalisation threshold for companies seeking to 'fast-track' their leaves out the smaller companies that have represented the bulk of IPOs over the past two decades.
Herald Sun
2 days ago
- Herald Sun
Stock Tips: Never mind the alpha, what's the Sigma play this week?
It's no easy gig analysing share prices and company performance but somebody's got to do it. Every week two experts from our Share Tips columnist pool give us their recommendations. Sean Conlan – Leyland Private Asset Management BUY Sigma Healthcare (ASX:SIG) We believe SIG will grow into its current PE multiple by refurbishing existing Chemist Warehouse stores, opening 20 new stores per annum across Australia and by exporting the brand offshore. Judo Capital Holdings (ASX:JDO) Improved funding costs give us more comfort on the near-term margin outlook. With forecast a~34% earnings CAGR over the next three years, and trading at only 12x FY26 P/E we think the valuation is attractive. HOLD Treasury Wine Estates (ASX:TWE) TWE has trimmed guidance for FY25 earnings growth, citing lower-than-expected wine sales in the US where economic uncertainty is hurting consumer demand. Austal (ASX:ASB) We remain positive on the long-term outlook for ASB, considering the macro tailwinds and attractive growth profile, however, we are conscious of its current valuation. SELL Bank of Queensland (ASX:BOQ) While BOQ's simplification strategy and pivot towards business is bearing fruit, we think it will continue to struggle to make returns above the cost of capital over the medium term. Lovisa Holdings (ASX:LOV) We are concerned about the quality of stores recently opened and think that higher-than-normal rates of discounting may be driving strong LFL sales. Chris Watt – Bell Potter Securities BUY CAR Group (CAR) Resilient RV sales, solid international operations and strong earnings momentum support continued growth. The company continues to benefit from a scalable global expansion strategy that allows it to replicate its model across international markets. Treasury Wine Estates (ASX:TWE) While the US premium wine market is weak, core luxury brands remain strong. DAOU Vineyards synergies and broader international opportunities provide upside despite recent downgrades. HOLD Technology One (ASX:TNE) A strong first-half result confirms the business is executing well, with growing recurring revenue and cash flow. However, recent share price gains limit short-term upside. James Hardie (ASX:JHX) Strategy execution in US new construction is on track, particularly in the southern states. That said, macro softness and affordability challenges persist. SELL IDP Education (ASX:IEL) Deteriorating student volumes and shifting global immigration policy have led to significant earnings downgrades. Visibility remains poor, and risks are elevated. Cettire (ASX:CTT) Weak margins, US tariff headwinds, and a soft cash position point to a challenging outlook. The path to profitability appears longer and riskier. The views, information, or opinions expressed in the interviews in this article are solely those of the interviewee and do not represent the views of Stockhead. Stockhead does not provide, endorse or otherwise assume responsibility for any financial advice contained in this article. Originally published as Stock Tips: Never mind the alpha, what's the Sigma play this week?
